Utilizing a ‘network’ analysis of proteins, Visterra’s innovative technology platform enables a more in depth structural understanding of proteins to (i) identify unique target epitopes and (ii) guide the design of novel drugs that specifically target these epitopes to effectively combat disease.
VIS410 – Monoclonal Antibody – Broad spectrum anti-viral therapy to transform the treatment and prevention of both seasonal and pandemic influenza.
Learn more »
| 11.09.12 | Visterra Secures Financing from Gates Foundation and Omega to Close $26M Series A Financing. Read more »  |
|---|---|
| 09.11.12 | Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, Vietnam. Read more » |